Sentinel node biopsy after neoadjuvant chemotherapy for node-positive breast cancer: Does axillary ultrasound improve performance? Comment uri icon


MeSH Major

  • Breast Neoplasms
  • Lymph Nodes


  • Copyright © 2015 American Society of Clinical Oncology. All rights reserved.A 66-year-old otherwise healthy woman palpates a lump in the lower inner quadrant of her left breast; she has no family history of breast or ovarian cancer and is not of Ashkenazi heritage. Clinical examination confirms a mobile 2-cm mass at 8:00 in her left breast; the axilla is clinically negative. Mammography is negative, but ultrasound (US) shows a 2.2-cm irregular hypoechoic nodule corresponding to the palpable mass, and US-guided core biopsy shows poorly differentiated invasive ductal carcinoma, triple negative (estrogen receptor, 0; progesterone receptor, 0; and human epidermal growth factor receptor 2, 0). US also notes a single suspicious 1-cm node in the left axilla, which US-guided core biopsy shows to be metastatic carcinoma (Fig 1). Clips placed to mark the sites of the breast and axillary biopsies are in appropriate position. She receives dose-dense neoadjuvant chemotherapy (NAC) with doxorubicin, cyclophosphamide, and paclitaxel, with completeresolution of her physical findings but with persistence of an abnormal left axillary node on US. She then has a left partial mastectomy with I-125 seed localization of the clip marking the core biopsy site and a left sentinel lymph node (SLN) biopsy using combined dye-isotope mapping. Final pathology confirms no cancer in the breast or in four SLNs; treatment effect is present in the breast and in the single SLN containing the clip placed at the time of biopsy.

publication date

  • October 20, 2015



  • Comment


Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.60.3316

PubMed ID

  • 26371144

Additional Document Info

start page

  • 3375

end page

  • 8


  • 33


  • 30